Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 Владивостокский Государственный медицинский университет; 2 ГБУЗ Краевой клинический центр специализированных видов медицинской помощи (материнства и детства); 3 МУЗ Городская клиническая больница №2, Владивосток
Список исп. литературыСкрыть список 1. Белоусов Ю.Б., Зырянов С.К., Белоусов Д.Ю., Бекетов А.С. Клинико-экономические аспекты терапии болезни Альцгеймера в России. Качественная клин. практика. 2009; с. 28. http://www.clinvest.ru/ part.php? pid=148 2. Гаврилова С.И., Селезнева Н.Д., Густов А.В. и др. Возможности превентивной терапии болезни Альцгеймера: результаты 3-летнего проспективного открытого сравнительного исследования эффективности и безопасности курсовой терапии Церебролизином и Винпоцетином у пожилых пациентов с синдромом мягкого когнитивного снижения. Журн. неврологии и психиатрии. 2010; 110 (1): 62–9. 3. Гаврилова С.И., Калын Я.Б. Эпидемиологические и фармакоэкономические аспекты болезни Альцгеймера. Психотерапия. 2008; 4: 7–12. 4. Гаврилова С.И., Федорова Я.Б., Колыхалов И.В. и др. АроЕ-генотип и эффективность нейротрофической и холинергической терапии при болезни Альцгеймера. Журн. неврологии и психиатрии. 2005; 105 (4): 27–33. 5. Селезнева Н.Д. Терапия деменции при болезни Альцгеймера. Автореф. дис. … д-ра мед. наук. М., 2002. http://www.psychiatry.ru/diss.php?dissnum=35 6. Чуканова Е.И. Патогенетические и клинические моменты применения Церебролизина. Трудный пациент. 2009; 6–7. http://www.t-pacient.ru/archive/tp6-7-09/tp5-6-09_584.html 7. Дамулин И.В. Применение Церебролизина при сосудистой деменции и болезни Альцгеймера. http://www.medlinks.ru/article.php?sid=11754 8. Alvarez A, Cacabelos R, Aleixandre M et al. Synergistic treatment effects with Cerebrolysin and donepezil: results from a randomized, double-blind, multicenter trial to compare safety and effiacy of Cerebrolysin, donepezil and a combination of both in patients with probable Alzheimer’s disease. Vienna. Intern Confer on Alzheimer’s Disease 2009. 9. Alvarez XA, Cacabelos R. Integrated clinical study report (EBE0 31010). A randomized, double-blind, clinical trial to compare the safety and efficacy of a Cerebrolysin and Aricept (donepezil) and a combination therapy in patients with probable Alzheimer’s disease. Unterach. Austria. EBEWE Neuro Pharma GmbH 2008. 10. Alvarez XA, Cacabelos R, Laredo M et al. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer’s disease. Eur J Neurol 2006; 13 (1): 43–54. 11. Alvarez XA, Cacabelos R, Sanpedro C et al. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer’s disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. Unterach, Austria. EBEWE Neuro Pharma GmbH 2009. 12. Alzheimer’s Association. 2009 Alheimer’s disease facts and figures. http://www.alz.org/national/documents/report_alzfactsfigures2009.pdf 13. Alzheimer’s Disease: Early Warning Signs and Diagnostic Resources. Used with the permission of The Junior League of NYC, Inc. 1988. 14. Bae CY, Cho CY, Cho K et al. A double-blind, placebocontrolled, multicenter study of Cerebrolysin for Alzheimer’s disease. J Am Geriatr Soc 2000; 48 (12): 1566–71. 15. Boado RJ. In vivo upregulation of the bloodbrain barrier GLUT1 glucose transporter by brainderived peptides. Eur J Neurol 1999; 6 (Suppl. 3): p. 37. 16. Dooley M, Lamb HM. Donepezil: a review of its use in Alzheimer’s disease. Drugs Aging 2000; 16 (3): 199–226. 17. Ferri CP, Prince M, Brayne C et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112–7. 18. Francis-Turner L, Valouskova V. Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbriafornix transection: shortterm study. Neurosci Lett 1996; 202: 193–6. 19. Francis Turner L, Valouskova V, Morky J. Longterm effect of NGF, bFGF and Cerebrolysin on the spatial memory after fimbriafornix lesion in rats. J Neural Trasm 1996; 47 (Suppl.): p. 277. 20. Gauthier S. Results of a 6 month randomized placebo controlled study with Cerebrolysin in Alzheimers disease. Eur J Neurol 1999; 6 (Suppl. 3): p. 28. 21. Gauthier SG, Boado RJ, Windisch M. Церебролизин – эффективность при лечении болезни Альцгеймера (результаты 6-месячного рандомизированного плацебо-контролируемого испытания эффективности Церебролизина при болезни Альцгеймера). Сons. Med. 2000; 2 (3). 22. Goldsmith DR, Scott LJ. Donepezil: in vascular dementia. Drugs Aging 2003; 20 (15): 1127–36. 23. Hartbauer M, Hutter-Paier B, Skofitsch G, Windisch M. Antiapoptotic effects of the peptidergic drug Cerebrolysin on primary cultures of embryonic chick cortical neurons. J Neural Transm 2001; 108: 459–73. 24. Jönhagen ME. Nerve growth factor treatment in dementia. Alzheimer Dis Assoc Disord 2000; 14 (Suppl. 1): 31–8. 25. Muresanu DF. Neuroprotection and neuroplasticity. A holistic approach and future perspectives. J Neurological Sciences 2007; 257: 38–43. 26. Muresanu DF, Rainer M, Moessler H. Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin. J Neural Transm 2002; 62: 277–85. 27. National Institute of Neurological Disorders and Stroke. National institutes of Health. Dementia: hope through research. http://www.ninds.nih.gov/disorders/dementias/detail_dementia.htm 28. Panisset M, Gauthier S, Moessler H et al. Cerebrolysin in Alzheimer’s disease: a randomized, double-blind, placebo controlled trial with a neurotrophic agent. J Neural Transm 2002; 109 (7–8): 1089–104. 29. Plosker GL, Gauthier S. Церебролизин. Аспекты применения при деменции. Практ. неврологу. 2010; 31 (1). http://neurology.mif-ua.com/archive/issue-11786/article-11841 30. Raina P, Santaguida P, Ismaila A et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008; 148: 379–97. 31. Robinson DM, Keating GM. Memantine: a review of its use in Alzheimer’s disease. Drugs 2006; 66 (11): 1515–34. 32. Robinson DM, Plosker GL. Galantamine extended release. CNS Drugs 2006; 20 (8): 673–81. 33. Ruether E, Alvarez XA, Rainer M et al. Sustained improvement of cognition and global function in patients with moderately severe Alzheimer’s disease: a doubleblind, placebo-controlled study with the neurotrophic agent Cerebrolysin. J Neural Transm 2002; 62: 265–75. 34. Ruether E, Husmann R, Kinzler E et al. A 28-week, doubleblind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer’s disease. Int Clin Psychopharmacol 2001; 16 (5): 253–63. 35. Ruеther E, Ritter R, Apecechea M et al. Efficacy of the peptidergic nootropic drug Cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiat 1994; 27 (1): 32–40. 36. Ruеther E, Ritter R, Apecechea M et al. Sustained improvements in patients with dementia of Alzheimer’s type (DAT) 6 months after termination of Cerebrolysin therapy. J Neural Transm 2000; 107 (7): 815–29. 37. Satou T, Imano M, Akai F et al. Morphological observation of effects of Cerebrolysin on culture neural cells. Adv Biosci 1993; 87: 195–6. 38. Scott LJ, Goa KL. Galantamine: a review of its use in Alzheimer’s disease. Drugs 2000; 60 (5): 1095–122. 39. Seow D, Gauthier S. Pharmacotherapy of Alzheimer disease. Can J Psychiatry 2007; 52 (10): 620–9. 40. Spencer CM, Noble S. Rivastigmine: a review of its use in Alzheimer’s disease. Drugs Aging 1998; 13 (5): 391–411. 41. Windisch M, Gschanes A, Hutter-Paier B. Neurotrophic activities and therapeutic experience with brain derived peptide preparation. J Neural Transm 1998; 53 (Suppl.): 289–98. 42. Xiao S, Yan H, Yao P et al. Efficacy of FPF1070 (Cerebrolysin) in patients with Alzheimer’s disease: a multicentre, randomised, double-blind, placebo-controlled trial. Clin Drug Invest 2000; 19 (1): 43–53. 43. Yang LPH, Keating GM. Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer’s type. CNS Drugs 2007; 21 (11): 957–65.